Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomised, Open-label Phase II Study to Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy

NCT03818685 is registered in ClinicalTrials.gov with Centre Leon Berard as lead sponsor.

NCT NCT03818685
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03818685 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomised, Open-label Phase II Study to Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy
Lead sponsor
Centre Leon Berard
Phase
Phase 2
Overall status
Unknown status
Start date
July 2, 2019
Completion date
May 1, 2024
Enrollment
95 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, triple negative breast neoplasms